Message from the BARDA Director: Thanks for supporting BARDA in 2020

About Image

As this year comes to an end, I want to thank you for making this year one of the most impactful in BARDA’s history.  Our BARDA COVID-19 Response Timeline provides a great recap of the work we performed together in response to the COVID pandemic.  However, COVID-19 activities are only part of our team’s accomplishments, we issued a solicitation for BARDA Ventures and together with our partners, we continued to support our traditional Chemical, Biological, Radiological and Nuclear threats, Pandemic Influenza and other Emerging Infectious Diseases.   

BARDA’s partnerships focus on the goal of ensuring products are available for Americans and the global community to save lives from national security threats.  This year we celebrated the successes of our partnerships with 4 FDA approvals, licensures or clearances for Pandemic Influenza, Zika and Ebola, and 20 Emergency Use Authorizations for COVID-19. 

I am proud to be part of this team. The BARDA team, our partners and our stakeholders will not rest until this mission is complete. What we have accomplished together inspires confidence that in 2021, we will continue to develop and deliver safe and effective medical countermeasures against COVID-19 and 21st Century Health Security Threats. 

Thank you for your partnership.  Stay safe and have a wonderful new year. 

Gary L. Disbrow Ph.D. 

Biomedical Advanced Research and Development Authority (BARDA) 
Deputy Assistant Secretary for Preparedness and Response 
Office of the Assistant Secretary for Preparedness and Response (ASPR) 
US Department of Health and Human Services (HHS) 


Last Updated: December 30, 2020

COVID-19 Medical Countermeasure Portfolio

This award is one component of BARDA's expanding COVID-19 medical countermeasure portfolio; visit BARDA's COVID-19 Portfolio to learn more.